Sometimes lucky is better than good. Recently, Caladrius picked up Shire’s global rights at late-stage (SHPG) also seen on the CD34+ stem cell therapy which is a no option angina refractory. This is a classic drug development acquisition story where the initial program was passed down. This was a continuous process starting at the Baxter (NYSE: BAX) proceeding to spinout basalt which was presently bought by the Shire.
Making things more clear and to the point, let me break down the acquisition of this late-stage refractory.
- The new CD34+ refractory angina present program has granted a regenerative advanced medical therapy last week.
- With promising mature and pipeline CD34+ and the availed $54M no debt cash, the stock undervalues at $65M which is a significant market cap.
- This acquisition will provide and give mature products for the CD34+ program with potential and good approval due to the treatment of the Caladrius which is refractory by angina from the Shire regulatory filings.
Although many clinical catalysts and updates re short term, then lots of results are recommended for short time gains. Nevertheless, more of this clinic catalysts take longer periods to play. This means that drug formulation and developments require dedication and more so patients in the developments keeping in mind the value creation and time need.
This is only possible cooperating with Biotech industries. According to Caladrius Bioscience acquisition, the recent CBS (Caladrius Biosciences) could boost their returns by investing in the acquisition of the late-stage refractory angina therapy from the Shire.
Remember the NeoStem Company which pulled its entire resources on the formulation of the dendritic immunotherapy cell which was to be treated at the advanced-stage of melanoma? This company stretched its resources to stage 3 where everything was pulled out due to unpromising results.
This is the same way that is currently doing but chance Caladrius Biosciences strike a gold in the last stage which involved the acquisition of this late-stage refractory angina therapy from the Shire which as we speak is used in entire clinics all over in treating this angina before reaching its latest stage.
This was a late result but has paid the Shire and this is considered hitting a Gold breakthrough in Biosciences research and formulation of the cure and therapy to late-stage refractory angina.